No resistance to elvitegravir (EVG), emtricitabine (FTC), lamivudine (3TC) or tenofovir (TFV)
Hepatic transaminases (AST and ALT) ≤ 5 x upper limit of normal (ULN)
No evidence of current hepatitis B virus (HBV) infection
No evidence of current hepatitis C virus (HCV) infection
Note: participants from Gilead Study GS-US-162-0112 were allowed to roll over into this Study GS-US-292-1515 even if they were 18 years or older at the time of screening.
You may not be if
A new AIDS-defining condition diagnosed within the 30 days prior to Screening
Evidence of active pulmonary or extra-pulmonary tuberculosis disease within 3 months of screening
Pregnant or lactating subjects
Clareo Health | Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Adolescents
